Comparison of the enteral and intravenous lansoprazole pharmacodynamic responses in critically ill patients

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 3, 2008, Pages 326-333

  Olsen, K M ^a,c   Devlin, J W ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DEMOGRAPHY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; FEMALE; GASTRIC PH MONITORING; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NASOGASTRIC TUBE; ORAL DISINTEGRATING TABLET; PHARMACODYNAMICS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STOMACH ACID SECRETION; STRESS ULCER; TABLET;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; CRITICAL ILLNESS; DRUG ADMINISTRATION ROUTES; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; INTENSIVE CARE UNITS; INTUBATION, GASTROINTESTINAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; STOMACH ULCER; TREATMENT OUTCOME;

EID: 63449109451     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03728.x     Document Type: Article

References (38)

1. Kahn JM, Doctor JN, Rubenfeld GD. Stress ulcer prophylaxis in mechanically ventilated patients: integrating evidence and judgment using a decision analysis. Intensive Care Med 2006; 32: 1151-8.
2. Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med 2004; 32: 2008-13.
3. Pisegna JR. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition. Crit Care Med 2002; 30(6 Suppl.): S356-61.
4. Conrad SA, Gabrielli A, Margolis B, et al. Randomized, double-blind comparison of immediate-release omepra- zole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005; 33: 760-5.
5. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998; 44: 527-33.
6. Phillips JO, Metzler MH, Huckfeldt RE, Olsen KM. A multicenter, prospective, randomized clinical trial of continuous infusion I.V. ranitidine vs. omeprazole suspension in the prophylaxis of stress ulcers. Crit Care Med 1998; 26 (Suppl. 1): 101A.
7. Phillips JO, Metzler MH, Palmieri MT, Huckfeldt RE, Dahl NG. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996; 24: 1793-800.
8. Phillips JO, Olsen KM, Rebuck JA, Ran- gnekar NJ, Miedema BW, Metzler MH. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol 2001; 96: 367-72.
9. Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations. Ann Pharmac- other 2005; 39: 1667-77.
10. Sharma VK, Peyton B, Spears T, Rauf- man JP, Howden CW. Oral pharmacoki- netics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000; 14: 887-92.
11. Tsai WL, Poon SK, Yu HK, et al. Naso- gastric lansoprazole is effective in suppressing gastric acid secretion in critically ill patients. Aliment Pharmacol Ther 2000; 14: 123-7.
12. Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm 1999; 23 (Sup- pl. 4): S18-21.
13. Song JC, Quercia RA, Fan C, Tsikouris J, White CM. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension. Am J Health Syst Pharm 2001; 58: 689-94.
14. Gremse DA, Donnelly JR, Kukulka MJ, Lloyd E, Lee C. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther 2004; 19: 1211-5.
15. Devlin JW, Bakshi A, Bungay K, Olsen KM. An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube. Aliment Pharmacol Ther 2006; 24: 1603-11.
16. White CM, Kalus JS, Quercia R, et al. Delivery of esomeprazole magnesium enteric-coated pellets through small caliber and standard nasogastric tubes and gastrostomy tubes in vitro. Am J Health Syst Pharm 2002; 59: 2085-8.
17. Armstrong D, Bair D, James C, Tanser L, Escobedo S, Nevin K. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2003; 18: 705-11.
18. Taubel JJ, Sharma VK, Chiu YL, Lukasik NL, Pilmer BL, Pan WJ. A comparison of simplified lansoprazole suspension administered nasogastrically and pan- toprazole administered intravenously: effects on 24-h intragastric pH. Aliment Pharmacol Ther 2001; 15: 1807-17.
19. Pisegna JR. Switching between intravenous and oral pantoprazole. J Clin Gas- troenterol 2001; 32: 27-32.
20. Freston JW, Pilmer BL, Chiu YL, et al. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lan- soprazole. Aliment Pharmacol Ther 2004; 19: 1111-22.
21. Bodenham A, Shelly MP, Park GR. The altered pharmacokinetics and pharma- codynamics of drugs commonly used in critically ill patients. Clin Pharmacoki- net 1988; 14: 347-73.
22. Mentec H, Dupont H, Bocchetti M, Cani P, Ponche F, Bleichner G. Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications. Crit Care Med 2001; 29: 1955-61.
23. Adam S, Batson S. A study of problems associated with the delivery of enteral feed in critically ill patients in five ICUs in the UK. Intensive Care Med 1997; 23: 261-6.
24. Freston J, Chiu YL, Pan WJ, Lukasik N, Taubel J. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Am J Gastroenterol 2001; 96: 2058-65.
25. Package insert. Prevacid Solutab (lanso- prazole). Lake Forest, IL: TAP Pharmaceutical Products. Available at: http:// www.pitap.abbott.com/ prevacidsolutab. pdf (accessed 12 March 2008).
26. Marik PE, Lorenzana A. Effect of tube feedings on the measurement of gastric intramucosal pH. Crit Care Med 1996; 24: 1498-500.
27. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
28. Olsen KM, Bergman KL, Kaufman SS, Rebuck JA, Collier D S. Omeprazole pharmacodynamics and gastric acid suppression in critically ill pediatric transplant patients. Pediatr Crit Care Med 2001; 2: 232-7.
29. Aoki I, Okumura M, Yashiki T. High- performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. J Chromatogr 1991; 571: 283-90.
30. Roland M, Tozer TN. Clinical Pharma- cokientics: Concepts and Applications. Philadelphia: Lea and Febiger, 1989.
31. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
32. Okabe S, Shimosako K, Amagase K. Pharmacological regulation of gastric acid secretion in the apical membrane of parietal cells; a new target for antise- cretory drugs. J Physiol Pharmacol 2001; 52 (4 Pt 1): 639-56.
33. Pisegna JR, Sostek MB, Monyak JT, Miner PB Jr. Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults. Aliment Pharmacol Ther 2008; 27: 483-90.
34. Freston JW, Chiu YL, Mulford DJ, Bal-lard ED 2nd. Comparative pharmacoki- netics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 361-7.
35. Freston JW, Kukulka MJ, Lloyd E, Lee C. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube. Aliment Pharmacol Ther 2004; 20: 40711.
36. Kanji S, McKinnon PS, Barletta JF, Kruse JA, Devlin JW. Bioavailability of gatifloxacin by gastric tube administration with and without concomitant ent- eral feeding in critically ill patients. Crit Care Med 2003; 31: 1347-52.
37. Metz DC, Devlin JW, Vakily M, Atkinson S, Lloyd E. Greater immediate gastric acid suppression with lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30- minute infusion. Pharmacotherapy 2008; 28: 301-7.
38. Brett S. Science review: the use of proton pump inhibitors for gastric acid suppression in critical illness. Crit Care 2005; 9: 45-50.